InvestSMART

Lumos Diagnostics Holdings Limited (ASX:LDX)

ALERT: Price-sensitive ASX Announcement for LDX
Current share price for LDX : $0.060 -0.04 (-40%)+
Announcement
Release
26 Aug 2026 9:44AM
Price at Release
$0.100
Full Release
download
Summary
In FY26, Lumos Diagnostics Holdings Limited reported a revenue increase of 6% to US$13.2 million, with a gross profit of US$7.9 million at a margin of 60.1%. The net loss after tax improved to US$5.0 million, and the adjusted EBITDA loss was reduced by 19% to US$2.8 million. Key achievements included a transformative U.S. distribution agreement worth US$317 million and a U.S. FDA CLIA waiver for FebriDx®, which expanded its U.S. market opportunity significantly. The company raised A$20.0 million to bolster U.S. commercialization efforts, successfully secured nationwide Medicare reimbursement, and plans to focus on scaling operations and increasing market penetration in FY27.
Key Points
  • FY26 revenue was US$13.2 million, up 6% over FY25.
  • Gross profit for FY26 was US$7.9 million with a gross margin of 60.1%.
  • Net loss after tax was US$5.0 million, improved from US$7.2 million in FY25.
  • Adjusted EBITDA loss for FY26 was US$2.8 million, a 19% improvement from FY25.
  • Significant milestones included a US$317 million U.S. distribution agreement and a U.S. FDA CLIA waiver for FebriDx®.
  • Completion of a A$20.0 million capital raise to support U.S. commercialization of FebriDx®.
  • Expansion of the addressable U.S. market for FebriDx® to over US$1.0 billion per annum.
  • Successful Medicare reimbursement coverage across all U.S. MAC jurisdictions.
  • Plans for FY27 focus on U.S. sales execution, expanding FebriDx® adoption, and scaling manufacturing.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.